Adverse Pregnancy Outcomes and the Heart: Reading the Whole Record

The individual articles in this pillar each take one pregnancy complication and read it forward. This one steps back to read the whole record. A woman’s pregnancy history may contain several adverse outcomes, and the cardiovascular signal lives less in any single one than in the pattern they form together. Read as a record rather than as isolated events, adverse pregnancy outcomes refine a woman’s risk in a way no single entry can.

The Mechanism

The physiological thread connecting adverse pregnancy outcomes to cardiovascular disease is shared biological susceptibility. Pregnancy is, in cardiovascular terms, a maximal stress test. Cardiac output rises by 30 to 50 percent. Blood volume expands by up to 50 percent. The vasculature must accommodate dramatically increased flow while maintaining normal perfusion pressures. The metabolic machinery must supply glucose and nutrients to the placenta and fetus while maintaining the mother’s own metabolic homeostasis. A woman whose vascular and metabolic systems are fully resilient tolerates these demands without incident. A woman with underlying vulnerabilities, in endothelial function, in vascular reactivity, in insulin sensitivity, in placental development, reveals those vulnerabilities under the physiological load of pregnancy.

Preeclampsia reveals specific abnormalities in placental vascular development and maternal endothelial function. The mechanism begins with defective deep placentation: in preeclampsia, the trophoblast cells that should remodel the spiral arteries of the uterus to become wide, low-resistance conduits fail to do so completely. The result is abnormal placental perfusion, which then triggers a systemic inflammatory and antiangiogenic response in the mother. Circulating levels of sFlt-1 (soluble fms-like tyrosine kinase-1), a protein that neutralizes pro-angiogenic factors, rise dramatically. The maternal endothelium becomes dysfunctional throughout the body, not just in the uterine vasculature. Blood pressure rises, proteinuria develops, and the same endothelial dysfunction that defines preeclampsia persists in attenuated form for years after delivery as a substrate for future atherosclerosis and hypertension.

Gestational diabetes reveals pre-existing limitations in beta-cell reserve and insulin sensitivity. The placental hormones of normal pregnancy induce physiological insulin resistance, and a woman who cannot compensate with increased insulin secretion develops gestational diabetes. The beta-cell limitation and underlying insulin resistance that pregnancy exposed remain after delivery, driving elevated long-term risk of type 2 diabetes, dyslipidemia, and cardiovascular disease.

Preterm birth, particularly at earlier gestational ages, is associated with inflammatory and vascular susceptibility that intersects with the risk factors for cardiovascular disease. The pathways overlap most heavily with preeclampsia, which is itself a leading cause of medically indicated preterm delivery.

Delivering a small-for-gestational-age infant reflects placental insufficiency, a failure of the uterine vasculature to deliver adequate nutrition to the fetus. This is a maternal vascular signature, and it shares biological ground with the vascular risk factors for cardiovascular disease.

The small-for-gestational-age mechanism deserves separate consideration because it operates somewhat differently from the others. When a baby is born small relative to its gestational age, the most common underlying cause is uteroplacental insufficiency: the blood supply to the placenta was inadequate to support normal fetal growth. This inadequacy reflects abnormalities in the same spiral artery remodeling that is impaired in preeclampsia, though the insufficiency in SGA pregnancies is often less severe, producing growth restriction without the dramatic blood pressure elevation that characterizes preeclampsia. The maternal vascular signature is nonetheless present, and it carries information about endothelial and vascular function that extends beyond the uterine circulation.

Women who deliver SGA infants without any hypertensive diagnosis are a particularly important population because they may not have any recorded pregnancy complication. The obstetric record may simply note a small baby. Without a clinician specifically connecting that note to a potential maternal cardiovascular signal, the information is likely to go uncounted in cardiovascular risk assessment indefinitely.

The common thread across all four recognized adverse pregnancy outcomes is revealed susceptibility in systems, vascular endothelium, metabolic regulation, inflammatory signaling, that overlap substantially with the systems implicated in atherosclerosis and cardiovascular disease. The pregnancy did not cause the cardiovascular risk; it uncovered the biological terrain on which future risk will develop.

What the Evidence Shows

The evidence base for adverse pregnancy outcomes as cardiovascular risk markers has matured substantially over the past two decades, and it now appears in major clinical guidelines.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, authored by Arnett et al., explicitly lists hypertensive disorders of pregnancy and premature menopause as female-specific risk-enhancing factors that should be used to inform statin therapy decisions in borderline-risk patients. Subsequent updates and the 2023 ACC/AHA Cardiovascular Disease Prevention Guidelines have reinforced this framing.

For preeclampsia, the data are most established. Bellamy et al. published a systematic review in The BMJ in 2007 covering over 3.5 million women across 25 studies, finding that preeclampsia was associated with approximately double the long-term risk of ischemic heart disease and stroke, and nearly 4-fold increased risk of hypertension. These associations persisted at follow-up intervals of more than a decade. 4 / Promising

The ARIC (Atherosclerosis Risk in Communities) study, which followed nearly 15,000 adults over several decades, contributed longitudinal data showing that women with pregnancy complications had accelerated subclinical atherosclerosis measurable years before clinical cardiovascular events. Parikh et al. and subsequent ARIC analyses confirmed that the pregnancy history added predictive value to standard risk factor models.

For gestational diabetes, Shah et al. publishing in JAMA Internal Medicine in 2016, following over 1 million Ontario women, found a 1.7-fold increased risk of premature cardiovascular disease compared to women without gestational diabetes in pregnancy, with the association persisting after adjustment for subsequent type 2 diabetes development.

For the combination of multiple outcomes, Crump et al. reported in JAMA Network Open that women with two or more adverse pregnancy outcomes had cardiovascular risks that substantially exceeded the risk from any single outcome. The additive nature of the reproductive risk stack has been confirmed across multiple cohorts: the signal from the whole record is stronger than the sum of its parts because multiple adverse outcomes increasingly point toward a woman with broad underlying biological susceptibility rather than a woman who experienced a single isolated complication.

The Women’s Health Study and the MESA (Multi-Ethnic Study of Atherosclerosis) have both contributed data showing that the reproductive risk factors carry predictive information that is independent of, and additive to, traditional Framingham-derived risk factors. Ridker et al. in the Women’s Health Study showed that inflammatory markers, including high-sensitivity CRP, added predictive value for cardiovascular events beyond standard lipid and blood pressure assessment. Women with adverse pregnancy history tend to have higher hsCRP values years after delivery, suggesting that the inflammatory susceptibility that contributed to the obstetric complication persists as a low-grade chronic state. This is why the reproductive record adds predictive information that the standard risk calculator, built on lipids, blood pressure, smoking, and age, cannot capture on its own.

The practical consequence is that a woman’s estimated 10-year cardiovascular risk from the Pooled Cohort Equations may meaningfully understate her true risk if she has a history of adverse pregnancy outcomes that has never been factored into the assessment. The ACC/AHA framework for risk-enhancing factors exists precisely to address this gap, but it only functions if the clinician knows the reproductive history. That requires the woman to volunteer it, specifically and completely, at the cardiovascular assessment visit.

Placental Abruption: The Less-Discussed Vascular Signal

Among adverse pregnancy outcomes with cardiovascular implications, placental abruption receives the least clinical attention in cardiovascular circles — partly because it is less common than preeclampsia and gestational diabetes, and partly because its mechanism involves thrombotic as well as vascular risk in ways that make its cardiovascular significance less immediately intuitive.

Placental abruption is the premature separation of the placenta from the uterine wall before delivery, occurring in approximately 1 percent of pregnancies. It is a medical emergency with significant fetal and maternal morbidity. What matters for cardiovascular risk assessment is what the obstetric event reveals about the underlying maternal vascular and coagulation biology.

The mechanisms that contribute to placental abruption overlap substantially with those driving cardiovascular disease. Endothelial dysfunction and reduced uteroplacental blood flow impair the placental attachment to the decidua. Abnormalities in coagulation — including reduced fibrinolytic capacity, relative hypercoagulability, and prothrombotic tendencies — further compromise placental adhesion. Chronic systemic inflammation, hypertension, and smoking all raise abruption risk through converging pathways that are mechanistically shared with atherosclerosis and coronary artery disease.

Rasmussen and colleagues, using Norwegian Medical Birth Registry data linked to national cardiovascular event registries and published in Hypertension in 2012, found that a history of placental abruption was associated with a 2.5-fold increase in subsequent ischemic heart disease risk over the decades following the affected pregnancy. The association held after controlling for smoking, hypertension, diabetes, and other established cardiovascular risk factors, indicating that abruption carried cardiovascular information independent of those factors.

The clinical gap is recognition. Women who have experienced placental abruption are not consistently informed that it may carry forward as a vascular signal. The ACC/AHA 2019 prevention guideline does not list abruption by name among the specific adverse pregnancy outcomes, though it is increasingly recognized in the cardiovascular literature as a marker of underlying vascular and thrombotic susceptibility.

Women with a history of abruption should include it in the complete pregnancy record brought to cardiovascular risk assessment, noting the gestational age at which it occurred and whether hypertension, preeclampsia, or fetal growth restriction was also present. These co-occurrences amplify the cardiovascular signal. A woman whose abruption occurred without any co-diagnosis may not have been told it carries cardiovascular relevance — volunteering it and asking that it be considered alongside other risk factors is how that information enters the clinical calculation.

What to Do This Week

1. Assemble your complete pregnancy record, including every adverse outcome across all pregnancies, not just the most severe or most recent. Include hypertensive disorders at any stage of pregnancy, gestational diabetes, preterm delivery at any gestational age, and any pregnancy in which the baby was described as small for gestational age or in which placental insufficiency was mentioned. The record matters in its entirety.

2. Bring the complete record into your next cardiovascular risk assessment and ask explicitly that each adverse outcome be counted as a risk-enhancing factor. You can reference the ACC/AHA framework directly: “I understand that hypertensive disorders of pregnancy and gestational diabetes are recognized as cardiovascular risk enhancers in the ACC/AHA prevention guidelines, and I want to make sure my full obstetric history is factored into my risk assessment.”

3. If you had more than one adverse outcome, or if you had a severe outcome such as preeclampsia requiring delivery before 34 weeks, ask your clinician specifically about earlier or more intensive cardiovascular monitoring. The combined signal from multiple outcomes may substantially exceed what your age-based Pooled Cohort Equations score suggests.

4. Verify that blood pressure, lipids, and fasting glucose or hemoglobin A1c are measured at least annually. Each of these standard risk factors deserves monitoring in any woman with adverse pregnancy history, and the monitoring frequency should be adjusted upward if any single value approaches a treatment threshold.

5. If you have had an adverse pregnancy outcome and are planning a subsequent pregnancy, disclose the full prior history at the first prenatal visit. Prior preeclampsia substantially raises the risk of preeclampsia in subsequent pregnancies, and prior gestational diabetes raises the risk of recurrence and of early-onset diabetes. The obstetric team needs the full record to manage the subsequent pregnancy appropriately.

There is an important asymmetry in how adverse pregnancy outcomes are weighted when they occur together. Two mild outcomes, such as a late-preterm delivery at 36 weeks without hypertension and borderline gestational glucose that did not meet formal gestational diabetes criteria, represent a different cardiovascular signal than one severe outcome such as preeclampsia with severe features before 34 weeks. The clinician assessing the record needs both the nature and the severity of each entry. For the woman bringing this history forward, providing that detail, including gestational age at delivery, highest blood pressure reached, whether NICU admission was required, and whether any medication was given during pregnancy, gives the clinician the information needed to weight the record correctly rather than simply noting “had complications in pregnancy.”

Adverse pregnancy outcomes carry their strongest cardiovascular signal when read as a whole record rather than as isolated events. The mechanism is shared biological susceptibility that pregnancy placed under physiological stress and revealed. Assembling the full pregnancy history, counting it as the risk-refining information it is, and bringing it into cardiovascular care is one of the most consequential corrections available in women’s heart disease prevention.